The rechargeable hearing aid producer has now raised more than $144m altogether, having collected about $52m in a series D round featuring Nan Fung Life Sciences.
US-based hearing aid provider Eargo received more than $52m in series D funding on Tuesday from investors including Nan Fung Life Sciences, a subsidiary of property development group Nan Fung.
The round also included venture capital firms New Enterprise Associates (NEA) and Maveron, the Charles and Helen Schwab Foundation and the Australian government-owned Future Fund.
Eargo produces rechargeable hearing aids that are made from medical-grade silicone and designed to be significantly smaller than traditional devices in the market, making them…
